Bulk Inquiry
Dasatinib
- BMS 354825 - Sprycel
- Soluble in DMSO
- MF: C22H26ClN7O2S
- MW: 488.01
Description
Dasatinib is an orally active dual BCR-ABL and Src family tyrosine kinase inhibitor. Dasatinib potently inhibits BCR-ABL kinase activity as well as multiple Src family kinases, resulting in suppression of oncogenic signaling pathways involved in cell proliferation, survival, migration, and differentiation.
BCR-ABL is a constitutively active fusion kinase that drives chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Src family kinases regulate diverse cellular processes including proliferation, adhesion, invasion, and immune signaling. Dasatinib is widely used as a research tool for studying kinase signaling and hematological malignancies.
Key Features
- Dual BCR-ABL and Src family kinase inhibitor
- Orally active compound
- Suppresses oncogenic tyrosine kinase signaling
- Targets BCR-ABL and multiple Src family kinases
- Widely used in leukemia and kinase signaling research
Applications
- BCR-ABL signaling research
- Src family kinase studies
- Leukemia and hematological cancer research
- Tyrosine kinase signaling investigations
- Cell proliferation and survival pathway studies
More Information
| Parent CAS No. | 302962-49-8 |
|---|---|
| Chemical Name | N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide |
| SMILES | C1C(C)=C(NC(=O)C2=CN=C(NC3=NC(C)=NC(N4CCN(CCO)CC4)=C3)S2)C(Cl)=CC=1 |
| MFCD | MFCD08704581 |
| InChi | InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) |
| InChiKey | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
| CID | 3062316 |
| Short Description | Bcr-Abl/Src inhibitor |
References
- M Talpaz et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med 2006, 354(24), 2531–41.
- JM Goldman, JV Melo. BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work? Acta Haematol 2008, 119, 212-217.
- Talpaz, M. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354(24), 2531-2541.
- List of publications using Dasatinib (Axon 1392) purchased from Axon Medchem.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1136 | SU 6656 |
From $132.00 |
| 1137 | PD180970 |
From $143.00 |
| 1394 | Imatinib mesylate |
From $66.00 |
| 1396 | Nilotinib |
From $55.00 |
| 1407 | SKI 606 |
From $82.50 |
| 1456 | AZD0530 difumarate |
From $115.50 |
| 1698 | A 770041 |
From $154.00 |
| 1857 | AP 24534 |
From $77.00 |
| 1882 | GNF 2 |
From $121.00 |
| 1892 | 1-NM-PP1 |
From $104.50 |
| 1941 | MLR 1023 |
From $104.50 |
| 2097 | CGP 77675 |
From $71.50 |
| 2121 | INNO 406 |
From $93.50 |
| 2123 | Rebastinib |
From $121.00 |
| 2219 | AT 9283 |
From $99.00 |
| 2366 | NG 25 trihydrochloride |
From $82.50 |
| 2381 | WH-4-023 |
From $99.00 |
| 2560 | Tilfrinib |
From $104.50 |
| 2757 | Asciminib |
From $132.00 |
| 2778 | Squarunkin A |
From $137.50 |
| 3099 | TL02-59 |
From $132.00 |
| 3168 | Nilotinib hydrochloride |
From $77.00 |
| 3284 | Saracatinib |
From $77.00 |
| 3973 | XL-228 |
From Inquiry |
